DOP2012000265A - Proteína de fusión robo1-fc y su utilización en el tratamiento de tumores. - Google Patents

Proteína de fusión robo1-fc y su utilización en el tratamiento de tumores.

Info

Publication number
DOP2012000265A
DOP2012000265A DO2012000265A DO2012000265A DOP2012000265A DO P2012000265 A DOP2012000265 A DO P2012000265A DO 2012000265 A DO2012000265 A DO 2012000265A DO 2012000265 A DO2012000265 A DO 2012000265A DO P2012000265 A DOP2012000265 A DO P2012000265A
Authority
DO
Dominican Republic
Prior art keywords
robo1
fusion protein
tumor treatment
protein
slit
Prior art date
Application number
DO2012000265A
Other languages
English (en)
Inventor
Francis Blanche
Beatrice Cameron
Tarik Dabdoubi
Pierre Fons
Jean-Pascal Herault
Catherine Prades
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42830780&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DOP2012000265(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of DOP2012000265A publication Critical patent/DOP2012000265A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/01—Hydrolysed proteins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Steroid Compounds (AREA)

Abstract

LA PRESENTE INVENCIÓN SE REFIERE A UNA PROTEÍNA RECOMBINANTE ROBO1-FC Y SU UTILIZACIÓN PARA TRATAR LAS ENFERMEDADES EN LAS QUE SE SOBREEXPRESA UNA PROTEÍNA SLIT, EN PARTICULAR CÁNCER. SE REFIERE IGUALMENTE A UNA COMPOSICIÓN QUE COMPRENDE TAL PROTEÍNA RECOMBINANTE. OTRO ASPECTO DE LA INVENCIÓN CONSISTE EN LA UTILIZACIÓN DE UNA MOLÉCULA ROBO1-FC COMO HERRAMIENTA DE DIAGNÓSTICO PARA DETECTAR LA SOBREEXPRESIÓN DE UNA MOLÉCULA DE LA FAMILIA SLIT EN UN PACIENTE.
DO2012000265A 2010-04-14 2012-10-05 Proteína de fusión robo1-fc y su utilización en el tratamiento de tumores. DOP2012000265A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1052829A FR2958936A1 (fr) 2010-04-14 2010-04-14 Proteine de fusion robo1-fc et son utilisation dans le traitement des tumeurs

Publications (1)

Publication Number Publication Date
DOP2012000265A true DOP2012000265A (es) 2013-02-28

Family

ID=42830780

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2012000265A DOP2012000265A (es) 2010-04-14 2012-10-05 Proteína de fusión robo1-fc y su utilización en el tratamiento de tumores.

Country Status (27)

Country Link
US (1) US9493529B2 (es)
EP (1) EP2558489A1 (es)
JP (1) JP5858442B2 (es)
KR (1) KR20130059329A (es)
CN (1) CN102884076A (es)
AR (1) AR080891A1 (es)
AU (1) AU2011239839B2 (es)
BR (1) BR112012026020A2 (es)
CA (1) CA2796303A1 (es)
CL (1) CL2012002879A1 (es)
CR (1) CR20120508A (es)
DO (1) DOP2012000265A (es)
EA (1) EA201291044A1 (es)
EC (1) ECSP12012230A (es)
FR (1) FR2958936A1 (es)
GT (1) GT201200275A (es)
IL (1) IL222382A (es)
MA (1) MA34221B1 (es)
MX (1) MX338981B (es)
NI (1) NI201200155A (es)
PE (1) PE20130199A1 (es)
PH (1) PH12012502044A1 (es)
SG (1) SG184529A1 (es)
TN (1) TN2012000473A1 (es)
TW (1) TW201142024A (es)
UY (1) UY33334A (es)
WO (1) WO2011128561A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5562986A (en) 1993-04-05 1996-10-08 Daikin Industries, Ltd. Polytetrafluoroethylene fibers, polytetrafluoroethylene materials and process for preparation of the same
AR084541A1 (es) * 2010-12-23 2013-05-22 Sanofi Sa PROTEINA DE FUSION ROBO1-Fc PARA SU USO EN EL TRATAMIENTO DEL HEPATOCARCINOMA
LT2800578T (lt) 2012-01-05 2019-02-11 Boston Medical Center Corporation Slit-robo signalo perdavimas, skirtas inkstų ligos diagnozavimui ir gydymui
US11566082B2 (en) 2014-11-17 2023-01-31 Cytiva Bioprocess R&D Ab Mutated immunoglobulin-binding polypeptides
CN107298715B (zh) * 2016-04-15 2021-05-04 阿思科力(苏州)生物科技有限公司 Slit2D2-嵌合抗原受体及其应用
US10703774B2 (en) 2016-09-30 2020-07-07 Ge Healthcare Bioprocess R&D Ab Separation method
JP7106187B2 (ja) 2016-05-11 2022-07-26 サイティバ・バイオプロセス・アールアンドディ・アクチボラグ 分離マトリックスを保存する方法
US10889615B2 (en) 2016-05-11 2021-01-12 Cytiva Bioprocess R&D Ab Mutated immunoglobulin-binding polypeptides
ES2909833T3 (es) 2016-05-11 2022-05-10 Cytiva Bioprocess R & D Ab Método de limpieza y/o desinfección de una matriz de separación
US10654887B2 (en) 2016-05-11 2020-05-19 Ge Healthcare Bio-Process R&D Ab Separation matrix
ES2874974T3 (es) 2016-05-11 2021-11-05 Cytiva Bioprocess R & D Ab Matriz de separación
JP7031934B2 (ja) 2016-05-11 2022-03-08 サイティバ・バイオプロセス・アールアンドディ・アクチボラグ 分離マトリックス
US10730908B2 (en) 2016-05-11 2020-08-04 Ge Healthcare Bioprocess R&D Ab Separation method
US12448411B2 (en) 2016-09-30 2025-10-21 Cytiva Bioprocess R&D Ab Separation method
CN110709415A (zh) * 2017-06-02 2020-01-17 辉瑞大药厂 重组robo2蛋白、组合物、方法及其用途
US11406682B2 (en) 2017-08-24 2022-08-09 Bar-Ilan University Roundabout (Robo) receptor inhibitors and uses thereof
BR112021016948A2 (pt) * 2019-02-27 2021-11-03 Daewoong Pharmaceutical Co Ltd Composição que compreende lrrd2 ligado à albumina de proteína slit3 para prevenção ou tratamento de doenças relacionadas a ossos e uso de lrrd2 ligado à albumina da proteína slit3
JP7696161B2 (ja) * 2019-04-23 2025-06-20 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 乳汁産生の促進に有用な組成物および方法
WO2025056020A1 (zh) * 2023-09-14 2025-03-20 北京拓界生物医药科技有限公司 包含robo结构域的蛋白及其医药用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6136310A (en) 1991-07-25 2000-10-24 Idec Pharmaceuticals Corporation Recombinant anti-CD4 antibodies for human therapy
US20060122373A1 (en) 1997-04-04 2006-06-08 Millennium Pharmaceuticals, Inc. Delta3, FTHMA-070, Tango85, Tango77, SPOIL,NEOKINE, Tango129 and integrin alpha subunit protein and nucleic acid molecules and uses thereof
AU729496B2 (en) * 1997-10-20 2001-02-01 Regents Of The University Of California, The Robo: a novel family of polypeptides and nucleic acids
WO1999051625A2 (en) * 1998-04-02 1999-10-14 Rigel Pharmaceuticals, Inc. Peptides causing formation of compact structures
EP1307557A2 (en) * 2000-08-02 2003-05-07 The Johns Hopkins University Endothelial cell expression patterns
DK1572169T3 (da) 2002-03-08 2013-10-21 Shanghai Inst Biol Sciences Påvisning og modulering af Slit- og Robo-medieret angiogenese og anvendelser deraf
EP1652923B1 (en) * 2003-08-08 2011-10-12 Perseus Proteomics Inc. Gene overexpressed in cancer
BRPI0507174A (pt) * 2004-01-28 2008-04-01 Syntonix Pharmaceuticals Inc proteìnas de fusão hormÈnio-fc (fsh-fc) heterodiméricas estimuladoras de folìculo para o tratamento da infertilidade
EP2738179A1 (en) * 2006-04-05 2014-06-04 AbbVie Biotechnology Ltd Antibody purification
AR063975A1 (es) 2006-11-28 2009-03-04 Centelion Fusiones fc con receptor para fgf soluble modificadas con actividad biologica mejorada
WO2008134046A1 (en) * 2007-04-27 2008-11-06 Genentech, Inc. Potent, stable and non-immunosuppressive anti-cd4 antibodies
PE20090993A1 (es) 2007-08-29 2009-07-08 Sanofi Aventis Anticuerpos anti-cxcr5 humanizados y derivados de los mismos
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof

Also Published As

Publication number Publication date
CA2796303A1 (fr) 2011-10-20
US20130039912A1 (en) 2013-02-14
MX2012011822A (es) 2012-11-12
PH12012502044A1 (en) 2017-07-26
EP2558489A1 (fr) 2013-02-20
KR20130059329A (ko) 2013-06-05
AU2011239839B2 (en) 2015-08-20
US9493529B2 (en) 2016-11-15
CN102884076A (zh) 2013-01-16
CL2012002879A1 (es) 2013-03-22
NI201200155A (es) 2013-02-05
AR080891A1 (es) 2012-05-16
EA201291044A1 (ru) 2013-04-30
TN2012000473A1 (fr) 2014-01-30
IL222382A0 (en) 2012-12-31
IL222382A (en) 2016-06-30
SG184529A1 (en) 2012-11-29
PE20130199A1 (es) 2013-03-09
WO2011128561A1 (fr) 2011-10-20
MX338981B (es) 2016-05-06
GT201200275A (es) 2014-01-24
JP2013523172A (ja) 2013-06-17
JP5858442B2 (ja) 2016-02-10
MA34221B1 (fr) 2013-05-02
CR20120508A (es) 2012-11-01
FR2958936A1 (fr) 2011-10-21
ECSP12012230A (es) 2012-11-30
TW201142024A (en) 2011-12-01
UY33334A (es) 2011-12-01
BR112012026020A2 (pt) 2016-06-28
AU2011239839A1 (en) 2012-11-08

Similar Documents

Publication Publication Date Title
GT201200275A (es) Proteína de fusión robo1-fc y su utilización en el tratamiento de tumores
MX2021006531A (es) Composicion que contiene arn para tratamiento de enfermedades tumorales.
PH12016501139A1 (en) Bicyclic heterocycle compounds and their uses in therapy
GT201400057A (es) 3-pirmidin-4-il-oxazolidin-2-onas como inhibidores de la idh mutante
MX2018005315A (es) Composiciones y metodos para el tratamiento del cancer.
BR112012012918A2 (pt) agente indutor de apoptose para o tratamento de câncer e de doenças imunes e autoimunes.
MX2015010372A (es) Objetivo terapeutico y de diagnostico para el cancer que comprende reactivos que se unen con dll3.
GT201200315A (es) Agentes inductores de apoptosis para el tratamiento del cáncer y de enfermedades inmunes y autoinmunes
UA107814C2 (uk) Спірооксіндольні антагоністи мdм2
IN2014MN02069A (es)
GT201200172A (es) Derivados de sulfonamida como agentes inductores de apoptosis con selectividad por bcl-2 para el tratamiento de cáncer y enfermedades inmunes
MX392752B (es) Terapia de combinacion para tratar cancer.
MX353482B (es) Metodos para el tratamiento del cancer y enfermedades inflamatorias utilizando cereblon como predictor.
BR112016004095A2 (pt) administração de enzimas de empobrecimento de quinurenina para a terapia contra tumores
BR112017009552A8 (pt) Métodos para alvejar o controle transcricional em regiões de super-realçador
MX2011008430A (es) Metodos y composiciones para diagnostico y tratamiento del cancer.
GT201500071A (es) Antiandrògenos para el tratamiento del cancer de prostata residente a la castracion no metastàsico3
MX377781B (es) Composiciones y metodos para diagnostico y tratamiento del cancer.
BR112013016107A2 (pt) molécula dimérica, método de tratamento de câncer, composição farmacêutica e kit para o diagnóstico de uma patologia ou tumor mediado(a) por upar
CO6741197A2 (es) Proteína de fusión robo1-fc para uso en el tratamiento del hepatocarcinoma
EP3164412A4 (en) Pharmaceutical composition comprising recombinant hemoglobin protein or subunit-based therapeutic agent for cancer targeting treatment
BR112015006656A8 (pt) composições e métodos para o tratamento de insuficiência cardíaca em pacientes diabéticos
BR112018006572A2 (pt) terapia de combinação racional para o tratamento de câncer
MX2018003308A (es) Suministro localizado de agente anti-fuctactico para tratamiento del cancer.
AR079052A1 (es) Tratamiento del accidente cerebrovascular isquemico agudo o sangrado intracraneal con activador tisular de plasminogeno (tpa) y eritropoyetina carbamilada